ilmscore | FII and DII are buying these 3 stocks?

FII and DII are buying these 3 stocks?

Predictions from this Video

Total: 9
Correct: 0
Incorrect: 0
Pending: 9
Prediction
Topic
Status
Polycab's solar products segment is predicted to become the largest contributor to its FMEG portfolio.
"This segment can now become the largest contributor to the FMEG portfolio."
POLYCAB
Pending
Polycab's EPC segment is expected to see revenue recovery in the second half of FY26.
"The management said that revenue recovery is expected in the second half of FY26 from the execution of these projects."
POLYCAB
Pending
Polycab's wires and cables segment is projected to grow 1.5-2x faster than the industry, targeting 11-13% margin within 5 years.
"the company says that the wires and cables segment will grow one and a half to two times faster than the industry and the target is to have a margin of 11 to 13% in the next 5 years."
POLYCAB
Pending
Polycab's annual capex of Rs 1,200-1,600 crore is expected to generate 4-5x incremental revenue, with impact delayed by 1.5-2 years.
"The company will invest Rs 1,200-1,600 crore annually, which could generate incremental revenues of approximately four to five times the capex. But this revenue impact will come with a delay of one and a half to two years."
POLYCAB
Pending
HBL management predicts that the strong Q2 FY26 electronics segment growth is unlikely to repeat in any single quarter for the next few years.
"Management expects that such strong results are unlikely to be seen again in any single quarter for the next few years."
HBL
Pending
HBL expects an annual order inflow of Rs 1300-1500 crore from Railways for the next 2-3 years.
"the management is expecting a steady inflow of Rs 1300 to 1500 crore annually for the next 2 to 3 years."
HBL
Pending
HBL's electronic fuses business is predicted to become a major business in the next few years.
"Fuses could become a major business in the next few years."
HBL
Pending
HBL management anticipates potential price pressure due to increased competition in niche markets.
"the management says that due to increased competition in niche markets, there may be further pressure on prices."
HBL
Pending
SIL Life Sciences management targets 15-20% revenue growth and 28-30% EBITDA margin within the next 2-3 years.
"the management's target is to achieve 15 to 20% revenue growth and 28 to 30% EBITDA margin in the next 2 to 3 years."
SIL Life Sciences
Pending